Ki-67 in screen-detected, low-grade, low-stage prostate cancer, relation to prostate-specific antigen doubling time, Gleason score and prostate-specific antigen relapse after radical prostatectomy

Scandinavian Journal of Urology and Nephrology

Volumn 43, Issue 1, 2009, Pages 12-18

  Khatami, Ali ^a   Hugosson, Jonas ^a   Wang, Wanzhong ^a   Damber, Jan Erik ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Ki 67; Prostate cancer; Radical prostatectomy; Screening

Indexed keywords

KI 67 ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RELAPSE; CANCER RISK; CONTROLLED STUDY; FOLLOW UP; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; RADICAL RETROPUBIC PROSTATECTOMY; TUMOR CELL;

AGED; BIOLOGICAL MARKERS; FEMALE; HUMANS; KI-67 ANTIGEN; MALE; MASS SCREENING; MIDDLE AGED; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 61649098448     PISSN: 00365599     EISSN: 16512065     Source Type: Journal    
DOI: 10.1080/00365590802469543     Document Type: Article

References (21)

1. Aus G, Abbou CC, Bolla M, Heidenreich A, Schmid HP, van Poppel H, et al. EAU guidelines on prostate cancer. Eur Urol 2005;48:546-51.
2. Bangma CH, Roemeling S, Schroder FH. Overdiagnosis and overtreatment of early detected prostate cancer. World J Urol 2007;25:3-9.
3. Bill-Axelson A, Holmberg L, Ruutu M, Haggman M, Andersson SO, Bratell S, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005;352:1977-84.
4. Klotz L. Active surveillance versus radical treatment for favorable-risk localized prostate cancer. Curr Treat Options Oncol 2006;7:355-62.
5. Hugosson J, Aus G, Lilja H, Lodding P, Pihl CG. Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma. Cancer 2004;100:1397-405.
6. Warlick C, Trock BJ, Landis P, Epstein JI, Carter HB. Delayed versus immediate surgical intervention and prostate cancer outcome. J Natl Cancer Inst 2006;98:355-7.
7. Khatami A, Aus G, Damber J-E, Lilja H, Lodding P, Hugosson J. PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: results from the European randomized study of screening for prostate cancer, Sweden section. Int J Cancer 2007;120:170-4.
8. Schmid HP, McNeal JE, Stamey TA. Clinical observations on the doubling time of prostate cancer. Eur Urol 1993;Suppl 2:60-3.
9. Railo M, Lundin J, Haglund C, von Smitten K, Nordling S. Ki-67, p53, ER receptors, ploidy and S phase as long-term prognostic factors in T1 node-negative breast cancer. Tumour Biol 2007;28:45-51.
10. Cowen D, Troncoso P, Khoo VS, Zagars GK, von Eschenbach AC, Meistrich ML, et al. Ki-67 staining is an independent correlate of biochemical failure in prostate cancer treated with radiotherapy. Clin Cancer Res 2002;8:1148-54.
11. Pollack A, DeSilvio M, Khor LY, Li R, Al-Saleem TI, Hammond ME, et al. Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02. J Clin Oncol 2004;22:2133-40.
12. Stattin P, Damber JE, Karlberg L, Bergh A. Cell proliferation assessed by Ki-67 immunoreactivity on formalin fixed tissues is a predictive factor for survival in prostate cancer. J Urol 1997;157:219-22.
13. Schroder FH, Denis LJ, Roobol M, Nelen V, Auvinen A, Tammela T, et al. The story of the European Randomized Study of Screening for Prostate Cancer. BJU Int 2003;92 Suppl 2:1-13.
14. Standaert B, Denis L. The European Randomized Study of Screening for Prostate Cancer: an update. Cancer 1997;80:1830-4.
15. Andren O, Fall K, Franzen L, Andersson SO, Johansson JE, Rubin MA. How well does the Gleason score predict prostate cancer death? A 20-year followup of a population based cohort in Sweden. J Urol 2006;175:1337-40.
16. Rubio J, Ramos D, Lopez-Guerrero JA, Iborra I, Collado A, Solsona E, et al. Immunohistochemical expression of Ki-67 antigen, cox-2 and Bax/Bcl-2 in prostate cancer; prognostic value in biopsies and radical prostatectomy specimens. Eur Urol 2005;48:745-51.
17. Freedland SJ, Humphreys EB, Mangold LA, EisenbergerM, Dorey FJ, Walsh PC, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005;294:433-9.
18. Roberts SG, Blute ML, Bergstralh EJ, Slezak JM, Zincke H. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc 2001;76:576-81.
19. Aaltomaa S, Lipponen P, Vesalainen S, Ala-Opas M, Eskelinen M, Syrjanen K. Value of Ki-67 immunolabelling as a prognostic factor in prostate cancer. Eur Urol 1997;32:410-5.
20. Bettencourt MC, Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Moul JW. Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy. J Urol 1996;156:1064-8.
21. Thompson SJ, Mellon K, Charlton RG, Marsh C, Robinson M, Neal DE. P53 and Ki-67 immunoreactivity in human prostate cancer and benign hyperplasia. Br J Urol 1992;69:609-13.